Biomarkers evaluation following MSC therapy in ALS patients
Phase 2
Completed
- Conditions
- Amyotrophic lateral sclerosis.Amyotrophic lateral sclerosisG12.21
- Registration Number
- IRCT20160809029275N5
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Patients with ALS confirmed by a neurologist with an ALSFRS-R score between 31-46.
Patients must have been treated with a stable dose of Rilozule for the previous 3 months.
Patients should not have any other chronic diseases and should not use ventilators.
Patients in the age range of 18 to 75 years.
Exclusion Criteria
Patients with malignancy.
Patients with other chronic diseases.
pregnancy.
Suffering from other neurodegenerative diseases.
Simultaneous participation in other clinical trials
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method